exp date isn't null, but text field is
***ONLY FOR USE BY CLINICIANS COMPETENT IN IV KETAMINE SEDATION***
The use of IV Ketamine for Paediatric Procedural Sedation within RHC ED is at the discretion of the ED consultant and ED nurse co-ordinator. Appropriate case selection and clinical demands of the rest of the department may influence the availability of this service. |
This SOP for IV Ketamine use in Procedural sedation can be adapted for use out with the Emergency Department however Minimum staffing , monitoring & equipment instructions should be replicated in the location the procedural sedation is being performed. Only CLINICIANS COMPETENT IN IV KETAMINE FOR SEDATION may prescribe and administer IV ketamine for emergency procedural sedation. During the COVID period the use of PPE for procedural sedation should follow the most up to date guidance released by Health Protection Scotland (HPS) with specific attention made to management for suspected/proven COVID positive versus non-COVID patients. Warning – interventions required to manage adverse reactions may result in aerosol generation procedures (ie – suctioning or positive pressure ventilation). PPE appropriate for these interventions should be used. |
Indications for use
STRICT contraindications
Use Ketamine sedation with added caution in these situations:
Airway Assessment
Modified ‘LEMON’ assessment: any issues that may contribute to a difficult intubation?
L: Look for facial abnormalities / dysmorphism.
E: Evaluation of mouth opening, tongue size, oral cavity, tonsil size, jaw position (retrognathia)
M: Mallampati score if applicable (see below – if Class 3 or 4 then inform ED Consultant in charge)
O: Obstruction - any signs of upper airway obstruction, stridor, drooling, difficulty with secretions.
N: Neck - assess neck mobility (check for limited extension / disproportionally short neck).
Mallampati score:
If there are any concerns identified on initial airway assessment above then these MUST be discussed with ED consultant in charge as part of the sedation approval process. |
Ketamine is a dissociative anaesthetic agent. Ketamine acts by binding to N-methyl-D-aspartate (NMDA) receptors and creates dissociation (disconnection) between the cortex and the limbic system and prevents the higher centres from perceiving visual, auditory or painful stimuli.
Ketamine produces a dissociative state characterised by profound analgesia, sedation, amnesia and immobilization. Protective airway reflexes and spontaneous respiration as well as cardiovascular stability are maintained.
Characteristics of ketamine dissociative state:
KETAMINE |
|
Route of administration |
Intravenous (IV) |
Clinical onset |
1 minute |
Duration of effective sedation |
15 minutes |
Recovery |
60 minutes |
Initial dose |
1mg/kg |
Subsequent dose |
0.25-0.5mg/kg |
Maximum dose |
2mg/kg |
Ondansetron - to be given prior to initial ketamine dose. |
|
Route of administration |
Intravenous (IV) |
Dose |
0.1mg/kg (max 4mg dose) – given over 30 seconds. |
Potential side effect |
Management |
Airway malposition (<1%) |
1. Airway repositioning manoeuvres +/- airway adjuncts as required. 2. If not resolved with above stop procedure and contact 84342 (anaesthetic on call) for assistance and prepare for rapid sequence intubation (RSI) with IV suxamethonium (2mg/kg) for paralysis. Continue airway and ventilation support efforts. |
Laryngospasm (0.3% ) |
1. Stop procedure. 2. Airway repositioning manoeuvres +/- adjuncts as required. 3. Direct suction of secretions using Yankauer suction catheter. 4. Provide PEEP with 100% oxygen delivered via T-Piece anaesthetic circuit. 5. If not resolved with above contact 84342 (anaesthetic on call) for assistance and prepare for rapid sequence intubation (RSI) with IV suxamethonium (2mg/kg) for paralysis. Continue airway and ventilation support efforts. |
Hyper-salivation |
1. Direct suction of secretions using Yankauer suction catheter 2. If persisting, stop procedure and administer IV atropine. |
Respiratory depression, apnoea |
1. Stop procedure 2. Provide ventilation via oxygen driven BVM / T-Piece anaesthetic circuit to prevent hypoxia. |
Cardiovascular depression
|
1. Stop procedure 3. Direct suction of secretions if present using Yankauer suction catheter 4. Administer IV atropine 5. If persisting then administer 10ml/kg fluid bolus of 0.9%NaCl. |
Emergence phenomena – transient psychotic effects, hallucinations, nightmares (more common beyond mid-adolescence) |
1. Reassurance for patient 2. Administer IV midazolam (50 micrograms/kg IV increments) for severe episodes. |
Nausea, vomiting |
1. Optimise patient position to avoid any aspiration risk.
|
Seizures – extremely rare |
1. Stop procedure and follow APLS guidance for seizures |
Allergy |
2. Stop procedure and follow APLS guidance for allergy/anaphylaxis. |
Diplopia, nystagmus, random purposeless movements, muscle twitching and rash are common |
No intervention required. |
Midazolam - for treatment of ‘emergence phenomena/agitation’ |
|
Route of administration |
Intravenous (IV) |
Dose |
50 micrograms/kg (0.05mg/kg) – given over 2-3minutes. (Max 6mg dose) |
Atropine – for treatment of hyper-salivation or bradycardia |
|
Route of administration |
Intravenous (IV) |
Initial dose
|
20 micrograms/kg (0.02mg/kg) – given over 2-3minutes. (Max 3mg dose) |
Drug action |
Anti-muscarinic agent that:
|
SUXAMETHONIUM – for paralysis in severe laryngospasm / airway compromise |
|
Route of administration |
Intravenous (IV) |
Dose |
2mg/kg |
Drug action |
Short acting neuromuscular blockade. |
Pre-sedation
Complete sedation checklist prior to procedure in all patients – meets criteria as above and possible contraindications assessed.
Analgesia
Minimum staff required - Depending on the procedure taking place additional medical or nursing staff may be required
Consent
Location
Equipment
All equipment must be checked and readily available prior to commencing emergency procedural sedation.
Monitoring
Documentation – procedure and sedation should be completed in Ketamine sedation proforma.
Post-procedure
Discharge from the Emergency Department
Green SM, Roback MG, Krauss B, Brown L, McGlone RG, Agrawal D, et al. Predictors of Airway and Respiratory Adverse Events With Ketamine Sedation in the Emergency Department: An Individual-Patient Data Meta-analysis of 8,282 Children. Ann Emerg Med. 2009;54(2)
Bhatt M, Johnson DW, Chan J, et al. Risk Factors for Adverse Events in Emergency Department Procedural Sedation for Children. JAMA Pediatr. 2017;171(10):957–964.
Bhatt M, Johnson DW, Taljaard M, et al. Association of Preprocedural Fasting With Outcomes of Emergency Department Sedation in Children. JAMA Pediatr. 2018;172(7):678–685.
Bellolio MF, Puls HA,Anderson JL, et al. Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis. BMJ Open 2016;6:e011384.
Langston WT, Wathen JE, Roback MG and Bajaj L. Effect of Ondansetron on the Incidence of Vomiting Associated With Ketamine Sedation in Children: A Double-Blind, Randomized, Placebo-Controlled Trial. Annals of Emergency Medicine 2008 Jul; 52(1):30-34.
Last reviewed: 01 June 2021
Next review: 30 June 2024
Author(s): Dr Steve Foster (Consultant in Paediatric Emergency Medicine, RHC Glasgow) & Dr Michael McCarron (Paediatric Trainee, RHC Glasgow)
Co-Author(s): Stakeholders: Dr Tony Moores (Consultant Paediatric anaesthetist, RHC Glasgow); Mr Stephen Bowhay (Lead Clinical Pharmacist, RHC Glasgow).
Approved By: RHC ED Clinical governance subgroup